Literature DB >> 17278975

Increased arterial stiffness in remote Indigenous Australians with high risk of cardiovascular disease.

Louise J Maple-Brown1, Leonard S Piers, Michael F O'Rourke, David S Celermajer, Kerin O'Dea.   

Abstract

OBJECTIVE: To assess central and peripheral arterial stiffness in Indigenous and European Australians with and without type 2 diabetes using applanation tonometry to obtain the augmentation index (AI) and pulse wave velocity (PWV).
METHODS: AI was assessed in 162 Indigenous Australians (60 with type 2 diabetes) participating in a population-based study and 121 Australians of European ancestry (38 with diabetes) of similar age and sex. PWV was assessed in a subgroup: n = 62 indigenous, n = 118 European participants.
RESULTS: The indigenous group had higher AI than the European group [mean (SD) 32 (12) versus 24 (12)%, P < 0.0001] and carotid-femoral PWV [8.4 (1.8) versus 7.1 (2.2) ms(-1), P < 0.0001]. There were no significant differences between groups regarding blood pressure and total cholesterol; however, indigenous individuals had higher fasting glucose, insulin, haemoglobin A1c, triglycerides, waist circumference (despite lower body mass index), and a higher prevalence of cigarette smoking. Fifty-five per cent of the variance in AI was explained on multiple regression analysis by age, sex, indigenous participant, heart rate, mean arterial pressure, height, triglycerides and waist circumference. Age, indigenous participant, heart rate, mean arterial pressure and antihypertensive medication explained 56% of the variance in PWV. Variables of the metabolic syndrome and smoking, C-reactive protein (CRP), homocysteine and heart rate clustered with indigenous status on factor analysis.
CONCLUSIONS: Indigenous Australians have higher indices of peripheral and central arterial stiffness than European Australians of similar age and sex. Factor analysis revealed that metabolic syndrome variables, smoking, CRP, homocysteine and heart rate clustered with 'indigenous participant' and may explain increased arterial stiffness in this group.

Entities:  

Mesh:

Year:  2007        PMID: 17278975     DOI: 10.1097/HJH.0b013e328011f766

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  6 in total

1.  Serum uric acid is associated with arterial stiffness in men with newly diagnosed type 2 diabetes mellitus.

Authors:  J Zhang; G Xiang; L Xiang; H Sun
Journal:  J Endocrinol Invest       Date:  2014-01-09       Impact factor: 4.256

2.  Is obesity predictive of cardiovascular dysfunction independent of cardiovascular risk factors?

Authors:  E DeVallance; S B Fournier; D A Donley; D E Bonner; K Lee; J C Frisbee; P D Chantler
Journal:  Int J Obes (Lond)       Date:  2014-06-24       Impact factor: 5.095

3.  Central-to-brachial blood pressure amplification in type 2 diabetes: a systematic review and meta-analysis.

Authors:  Rachel E Climie; Martin G Schultz; James W Fell; Lorena Romero; Petr Otahal; James E Sharman
Journal:  J Hum Hypertens       Date:  2018-11-13       Impact factor: 3.012

4.  Abdominal obesity and other risk factors largely explain the high CRP in indigenous Australians relative to the general population, but not gender differences: a cross-sectional study.

Authors:  Allison M Hodge; Louise Maple-Brown; Joan Cunningham; Jacqueline Boyle; Terry Dunbar; Tarun Weeramanthri; Jonathan Shaw; Kerin O'Dea
Journal:  BMC Public Health       Date:  2010-11-15       Impact factor: 3.295

5.  Continuing disparities in cardiovascular risk factors and complications between aboriginal and Anglo-Celt Australians with type 2 diabetes: the Fremantle Diabetes Study.

Authors:  Timothy M E Davis; Kerry Hunt; Daniel McAullay; Stephen A P Chubb; Brett A Sillars; David G Bruce; Wendy A Davis
Journal:  Diabetes Care       Date:  2012-07-18       Impact factor: 19.112

6.  Closing the Gaps: competing estimates of Indigenous Australian life expectancy in the scientific literature.

Authors:  Amanda Rosenstock; Bryan Mukandi; Anthony B Zwi; Peter S Hill
Journal:  Aust N Z J Public Health       Date:  2013-08       Impact factor: 2.939

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.